Who is sponsoring NCT05679102?

NCT05679102 is sponsored by Himayat Ullah.

What drugs are being tested in NCT05679102?

Interventions in NCT05679102: Amlodipine 5 MG Oral Tablet, Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet.

What condition does NCT05679102 study?

NCT05679102 studies Atorvastatin Antihypertensive Effect.

Is NCT05679102 still recruiting?

NCT05679102 is currently completed. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT05679102

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atorvastatin as an Antihypertensive Agent

Completed NA Last updated 10 January 2023

What this trial tests

NA trial testing Amlodipine 5 MG Oral Tablet in Atorvastatin Antihypertensive Effect in 120 participants. Completed in 4 January 2023.

Timeline

20 December 2022

Primary endpoint
4 January 2023

4 January 2023

Quick facts

Lead sponsor	Himayat Ullah
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	20 December 2022
Primary completion	4 January 2023
Estimated completion	4 January 2023
Sites	1 location across Saudi Arabia

Drugs / interventions tested

Amlodipine 5 MG Oral Tablet
Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet — full drug profile →

Conditions studied

Atorvastatin Antihypertensive Effect — all drugs for Atorvastatin Antihypertensive Effect →

Sponsor

Himayat Ullah — full company profile →

Who can join

35 and older, any sex, with Atorvastatin Antihypertensive Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is aimed to see the antihypertensive effect of statin (Atorvastatin) as certain animal models have shown that statins have the voltage-gated calcium channel blocking effect. It will be a randomized controlled trial that will be done in Ayub Hospital Complex Abbottabad. After ethical approval, 120 patients with newly diagnosed hypertension belonging to either gender and aged 35 and above will be enrolled in the trial. They will randomly be grouped into two groups with each group comprising 60 patients. One group will be administered Amlodipine 5 mg PO once a day, while the other one will be given 5mg Amlodipine plus 10 mg Atorvastatin. The patients will be examined on a follow-up visit 14 days later and blood pressure will be recorded as per protocols.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Atorvastatin as an Antihypertensive Agent: A Pilot Study.
Ali N, Faheem M, Ullah H, Shabana H, et al · · 2023 · cited 1× · PMID 38156151 · DOI 10.7759/cureus.49532

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05679102 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Himayat Ullah
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05679102.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing